Literature DB >> 19019843

Cell discohesion and multifocality of carcinoma in situ of the bladder: new insight from the adhesion molecule profile (e-cadherin, Ep-CAM, and MUC1).

Carlo Patriarca1, Piergiuseppe Colombo, Angelo Pio Taronna, Jelle Wesseling, Giada Franchi, Francesca Guddo, Richard Naspro, Roberto Maria Macchi, Paolo Giunta, Marcello Di Pasquale, Michele Parente, Carmelo Arizzi, Massimo Roncalli, Biagio Campo.   

Abstract

Urothelial cell carcinoma in situ (CIS) of the bladder is a superficially diffusive and highly discohesive disease. The authors analyzed the expression of some adhesion molecules (e-cadherin and Ep-CAM) and MUC1 in 32 unifocal and multifocal bladder urothelial cell CIS in an attempt to clarify this discohesion. E-cadherin was strongly expressed, in more than 75% of the cases. The presence of methylation of the CDH1 e-cadherin promoter gene was also investigated, but methylation was found in only one case. Ep-CAM was present in all the cases with a heterogeneous staining pattern. Similarly, MUC1/episialin was variously present in 94% of the cases without a polarized staining pattern and was expressed more strongly in cases with multifocal disease. Because loss of MUC1 polarization leads to interference with cell-cell adhesion mechanisms mediated by cadherins, these findings help explain why bladder urothelial cell CIS often shows a discohesive morphology and multifocality despite a strongly expressed adhesion molecule profile. Finally, Ep-CAM expression might provide some support for future target therapy trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019843     DOI: 10.1177/1066896908326918

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  5 in total

Review 1.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

2.  Different subtypes of carcinoma in situ of the bladder do not have a different prognosis.

Authors:  Eva Compérat; Solene-Florence Jacquet; Justine Varinot; Pierre Conort; Morgan Roupret; Emmanuel Chartier-Kastler; Marc-Olivier Bitker; Johannes Alfred Witjes; Olivier Cussenot
Journal:  Virchows Arch       Date:  2013-02-10       Impact factor: 4.064

3.  Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis.

Authors:  Sukhwinder Kaur; Navneet Momi; Subhankar Chakraborty; David G Wagner; Adam J Horn; Subodh M Lele; Dan Theodorescu; Surinder K Batra
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

Review 4.  Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.

Authors:  Seyed Mehdi Havaei; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

5.  Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential.

Authors:  R T Bryan; N J Shimwell; W Wei; A J Devall; S J Pirrie; N D James; M P Zeegers; K K Cheng; A Martin; D G Ward
Journal:  Br J Cancer       Date:  2013-11-28       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.